ERBB2 and neoplasm: Moreover, by evidencing tumor-driven differences in immune response, these models can be useful to capture the diversity of tumor response against novel anti-HER2 agents, such as the recently approved monoclonal antibody margetuximab (142, 143) and the antibody-drug conjugate trastuzumab-deruxtecan (144).